GeneCentric Therapeutics to Present Data on Potential of its Cancer Subtyping Platform to Identify Responders to PARP Inhibitors for Treating Lung Cancer

Durham, NC, October 26, 2017— GeneCentric Therapeutics announced today that it will present data on the potential of non-small cell lung cancer (NSCLC) biologic subtypes based on its Cancer Subtyping Platform (CSP®) to provide novel biomarkers for response to PARP inhibitors. The data will be presented at a poster session during the 2017 American Association for Cancer Research – National Cancer Institute – European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Therapeutics being held October 27-30, 2017 at the Philadelphia Convention Center, Philadelphia, PA.

Data to be Presented at 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference


Leave a Reply

Your email address will not be published. Required fields are marked *